A. Borrero-palacios

Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

A. Cebrián, J. García-Foncillas, T. Gómez del Pulgar, 2016, Pathology, research and practice.

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

A. Cebrián, F. Rojo, M. Soengas, 2014, BMC Cancer.

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

F. Rojo, J. Madoz-Gúrpide, S. Zazo, 2014, British Journal of Cancer.

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

M. Fraga, F. Rojo, S. Zazo, 2016, Oncotarget.